Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aisling raises $650 million for new fund

This article was originally published in Scrip

Executive Summary

The private equity firm Aisling Capital has raised $650 million for a new life sciences fund, Aisling Capital III. The New York-based company will invest primarily in companies developing pharmaceutical, biopharmaceutical and medical products, but also in those that provide drug development, manufacturing and other services to the pharmaceutical industry. One of Aisling's investor companies, Map Pharmaceuticals, signed a $900 million co-development and commercialisation deal with AstraZeneca last month for Map's unit dose budesonide (Scrip Online, December 22nd, 2008).


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts